nodes	percent_of_prediction	percent_of_DWPC	metapath
Crizotinib—MERTK—Parkinson's disease	0.306	0.444	CbGaD
Crizotinib—IGF1R—Parkinson's disease	0.214	0.31	CbGaD
Crizotinib—ABL1—Parkinson's disease	0.143	0.208	CbGaD
Crizotinib—ABCB1—Parkinson's disease	0.0265	0.0384	CbGaD
Crizotinib—RPS6KB1—medulla oblongata—Parkinson's disease	0.000228	0.00179	CbGeAlD
Crizotinib—CSF1R—forebrain—Parkinson's disease	0.000228	0.00179	CbGeAlD
Crizotinib—RIPK2—spinal cord—Parkinson's disease	0.000228	0.00179	CbGeAlD
Crizotinib—AURKA—nervous system—Parkinson's disease	0.000228	0.00179	CbGeAlD
Crizotinib—LIMK2—head—Parkinson's disease	0.000227	0.00178	CbGeAlD
Crizotinib—TNK2—cerebellum—Parkinson's disease	0.000226	0.00177	CbGeAlD
Crizotinib—IGF1R—cerebellum—Parkinson's disease	0.000226	0.00177	CbGeAlD
Crizotinib—AXL—medulla oblongata—Parkinson's disease	0.000226	0.00177	CbGeAlD
Crizotinib—CDK7—brain—Parkinson's disease	0.000226	0.00177	CbGeAlD
Crizotinib—TESK1—nervous system—Parkinson's disease	0.000226	0.00177	CbGeAlD
Crizotinib—TIE1—central nervous system—Parkinson's disease	0.000225	0.00177	CbGeAlD
Crizotinib—MAP3K12—head—Parkinson's disease	0.000224	0.00176	CbGeAlD
Crizotinib—ACVR1—head—Parkinson's disease	0.000224	0.00176	CbGeAlD
Crizotinib—TAOK2—brain—Parkinson's disease	0.000224	0.00176	CbGeAlD
Crizotinib—MAP4K2—cerebellum—Parkinson's disease	0.000223	0.00175	CbGeAlD
Crizotinib—STK10—cardiovascular system—Parkinson's disease	0.000221	0.00174	CbGeAlD
Crizotinib—TAOK3—cardiovascular system—Parkinson's disease	0.000221	0.00173	CbGeAlD
Crizotinib—STK3—cerebellum—Parkinson's disease	0.00022	0.00173	CbGeAlD
Crizotinib—TIE1—cerebellum—Parkinson's disease	0.00022	0.00173	CbGeAlD
Crizotinib—MERTK—nervous system—Parkinson's disease	0.00022	0.00172	CbGeAlD
Crizotinib—STK35—head—Parkinson's disease	0.00022	0.00172	CbGeAlD
Crizotinib—AURKA—central nervous system—Parkinson's disease	0.000219	0.00172	CbGeAlD
Crizotinib—SLK—medulla oblongata—Parkinson's disease	0.000218	0.00171	CbGeAlD
Crizotinib—TESK1—central nervous system—Parkinson's disease	0.000217	0.00171	CbGeAlD
Crizotinib—TBK1—midbrain—Parkinson's disease	0.000217	0.0017	CbGeAlD
Crizotinib—PTK2—midbrain—Parkinson's disease	0.000217	0.0017	CbGeAlD
Crizotinib—EPHB4—medulla oblongata—Parkinson's disease	0.000216	0.0017	CbGeAlD
Crizotinib—EPHA3—brain—Parkinson's disease	0.000216	0.0017	CbGeAlD
Crizotinib—ACVR1B—brain—Parkinson's disease	0.000216	0.0017	CbGeAlD
Crizotinib—TYK2—midbrain—Parkinson's disease	0.000215	0.00169	CbGeAlD
Crizotinib—SRC—cardiovascular system—Parkinson's disease	0.000215	0.00169	CbGeAlD
Crizotinib—LIMK2—nervous system—Parkinson's disease	0.000215	0.00169	CbGeAlD
Crizotinib—JAK2—medulla oblongata—Parkinson's disease	0.000214	0.00168	CbGeAlD
Crizotinib—IRAK1—midbrain—Parkinson's disease	0.000213	0.00167	CbGeAlD
Crizotinib—ACVR1—nervous system—Parkinson's disease	0.000213	0.00167	CbGeAlD
Crizotinib—MAP3K12—nervous system—Parkinson's disease	0.000213	0.00167	CbGeAlD
Crizotinib—TESK1—cerebellum—Parkinson's disease	0.000213	0.00167	CbGeAlD
Crizotinib—PTK2—spinal cord—Parkinson's disease	0.000212	0.00166	CbGeAlD
Crizotinib—TBK1—spinal cord—Parkinson's disease	0.000212	0.00166	CbGeAlD
Crizotinib—MERTK—central nervous system—Parkinson's disease	0.000212	0.00166	CbGeAlD
Crizotinib—BMP2K—head—Parkinson's disease	0.000211	0.00166	CbGeAlD
Crizotinib—TYK2—spinal cord—Parkinson's disease	0.00021	0.00165	CbGeAlD
Crizotinib—RPS6KB1—midbrain—Parkinson's disease	0.000209	0.00164	CbGeAlD
Crizotinib—STK35—nervous system—Parkinson's disease	0.000208	0.00164	CbGeAlD
Crizotinib—LIMK2—central nervous system—Parkinson's disease	0.000207	0.00162	CbGeAlD
Crizotinib—MERTK—cerebellum—Parkinson's disease	0.000207	0.00162	CbGeAlD
Crizotinib—MAP4K5—medulla oblongata—Parkinson's disease	0.000207	0.00162	CbGeAlD
Crizotinib—MAP3K3—medulla oblongata—Parkinson's disease	0.000207	0.00162	CbGeAlD
Crizotinib—TEK—medulla oblongata—Parkinson's disease	0.000207	0.00162	CbGeAlD
Crizotinib—AXL—midbrain—Parkinson's disease	0.000207	0.00162	CbGeAlD
Crizotinib—EPHA6—brain—Parkinson's disease	0.000206	0.00162	CbGeAlD
Crizotinib—JAK3—brain—Parkinson's disease	0.000206	0.00162	CbGeAlD
Crizotinib—DCLK1—brain—Parkinson's disease	0.000205	0.00161	CbGeAlD
Crizotinib—ACVR1—central nervous system—Parkinson's disease	0.000205	0.00161	CbGeAlD
Crizotinib—MAP3K12—central nervous system—Parkinson's disease	0.000205	0.00161	CbGeAlD
Crizotinib—PTK2B—head—Parkinson's disease	0.000204	0.0016	CbGeAlD
Crizotinib—ABL1—embryo—Parkinson's disease	0.000204	0.0016	CbGeAlD
Crizotinib—RPS6KB1—spinal cord—Parkinson's disease	0.000204	0.0016	CbGeAlD
Crizotinib—PLK4—brain—Parkinson's disease	0.000203	0.0016	CbGeAlD
Crizotinib—RIPK2—head—Parkinson's disease	0.000203	0.00159	CbGeAlD
Crizotinib—STK4—brain—Parkinson's disease	0.000202	0.00159	CbGeAlD
Crizotinib—LIMK2—cerebellum—Parkinson's disease	0.000202	0.00159	CbGeAlD
Crizotinib—AXL—spinal cord—Parkinson's disease	0.000201	0.00158	CbGeAlD
Crizotinib—NUAK2—cerebellum—Parkinson's disease	0.000201	0.00158	CbGeAlD
Crizotinib—STK35—central nervous system—Parkinson's disease	0.000201	0.00157	CbGeAlD
Crizotinib—BMP2K—nervous system—Parkinson's disease	0.0002	0.00157	CbGeAlD
Crizotinib—ACVR1—cerebellum—Parkinson's disease	0.0002	0.00157	CbGeAlD
Crizotinib—MAP3K12—cerebellum—Parkinson's disease	0.0002	0.00157	CbGeAlD
Crizotinib—FLT3—cerebellum—Parkinson's disease	0.0002	0.00157	CbGeAlD
Crizotinib—SLK—midbrain—Parkinson's disease	0.000199	0.00156	CbGeAlD
Crizotinib—EPHB6—medulla oblongata—Parkinson's disease	0.000198	0.00155	CbGeAlD
Crizotinib—EPHB4—midbrain—Parkinson's disease	0.000197	0.00155	CbGeAlD
Crizotinib—STK35—cerebellum—Parkinson's disease	0.000196	0.00154	CbGeAlD
Crizotinib—EPHA4—head—Parkinson's disease	0.000196	0.00154	CbGeAlD
Crizotinib—SLK—spinal cord—Parkinson's disease	0.000194	0.00152	CbGeAlD
Crizotinib—PTK2B—nervous system—Parkinson's disease	0.000194	0.00152	CbGeAlD
Crizotinib—BMP2K—central nervous system—Parkinson's disease	0.000193	0.00152	CbGeAlD
Crizotinib—CSF1R—cardiovascular system—Parkinson's disease	0.000193	0.00151	CbGeAlD
Crizotinib—EPHB4—spinal cord—Parkinson's disease	0.000193	0.00151	CbGeAlD
Crizotinib—MAP3K2—head—Parkinson's disease	0.000192	0.00151	CbGeAlD
Crizotinib—JAK2—spinal cord—Parkinson's disease	0.000191	0.0015	CbGeAlD
Crizotinib—EPHA5—brain—Parkinson's disease	0.000191	0.0015	CbGeAlD
Crizotinib—FER—brain—Parkinson's disease	0.000191	0.0015	CbGeAlD
Crizotinib—ALK—brain—Parkinson's disease	0.000191	0.0015	CbGeAlD
Crizotinib—TYRO3—brain—Parkinson's disease	0.000191	0.0015	CbGeAlD
Crizotinib—ABL2—cerebellum—Parkinson's disease	0.000191	0.0015	CbGeAlD
Crizotinib—YES1—medulla oblongata—Parkinson's disease	0.000191	0.0015	CbGeAlD
Crizotinib—LYN—brain—Parkinson's disease	0.00019	0.00149	CbGeAlD
Crizotinib—TNK1—brain—Parkinson's disease	0.000189	0.00148	CbGeAlD
Crizotinib—MAP3K3—midbrain—Parkinson's disease	0.000189	0.00148	CbGeAlD
Crizotinib—TEK—midbrain—Parkinson's disease	0.000189	0.00148	CbGeAlD
Crizotinib—MAP4K5—midbrain—Parkinson's disease	0.000189	0.00148	CbGeAlD
Crizotinib—BMP2K—cerebellum—Parkinson's disease	0.000189	0.00148	CbGeAlD
Crizotinib—TAOK3—medulla oblongata—Parkinson's disease	0.000188	0.00148	CbGeAlD
Crizotinib—PTK2—head—Parkinson's disease	0.000188	0.00148	CbGeAlD
Crizotinib—TBK1—head—Parkinson's disease	0.000188	0.00148	CbGeAlD
Crizotinib—BMPR1B—brain—Parkinson's disease	0.000187	0.00147	CbGeAlD
Crizotinib—MAP4K1—brain—Parkinson's disease	0.000187	0.00147	CbGeAlD
Crizotinib—MAP3K19—brain—Parkinson's disease	0.000187	0.00147	CbGeAlD
Crizotinib—ABL1—brainstem—Parkinson's disease	0.000187	0.00147	CbGeAlD
Crizotinib—TYK2—head—Parkinson's disease	0.000187	0.00147	CbGeAlD
Crizotinib—PTK2B—central nervous system—Parkinson's disease	0.000186	0.00146	CbGeAlD
Crizotinib—EPHA4—nervous system—Parkinson's disease	0.000186	0.00146	CbGeAlD
Crizotinib—TEK—spinal cord—Parkinson's disease	0.000184	0.00145	CbGeAlD
Crizotinib—MAP3K3—spinal cord—Parkinson's disease	0.000184	0.00145	CbGeAlD
Crizotinib—MAP4K5—spinal cord—Parkinson's disease	0.000184	0.00145	CbGeAlD
Crizotinib—TNK2—brain—Parkinson's disease	0.000184	0.00144	CbGeAlD
Crizotinib—IGF1R—brain—Parkinson's disease	0.000184	0.00144	CbGeAlD
Crizotinib—PTK2B—cerebellum—Parkinson's disease	0.000182	0.00143	CbGeAlD
Crizotinib—MAP3K2—nervous system—Parkinson's disease	0.000182	0.00143	CbGeAlD
Crizotinib—MAP4K2—brain—Parkinson's disease	0.000181	0.00142	CbGeAlD
Crizotinib—RPS6KB1—head—Parkinson's disease	0.000181	0.00142	CbGeAlD
Crizotinib—RIPK2—cerebellum—Parkinson's disease	0.000181	0.00142	CbGeAlD
Crizotinib—EPHB6—midbrain—Parkinson's disease	0.000181	0.00142	CbGeAlD
Crizotinib—FGR—head—Parkinson's disease	0.00018	0.00141	CbGeAlD
Crizotinib—AXL—head—Parkinson's disease	0.000179	0.00141	CbGeAlD
Crizotinib—EPHA4—central nervous system—Parkinson's disease	0.000179	0.0014	CbGeAlD
Crizotinib—STK3—brain—Parkinson's disease	0.000179	0.0014	CbGeAlD
Crizotinib—TIE1—brain—Parkinson's disease	0.000179	0.0014	CbGeAlD
Crizotinib—PTK2—nervous system—Parkinson's disease	0.000178	0.0014	CbGeAlD
Crizotinib—TBK1—nervous system—Parkinson's disease	0.000178	0.0014	CbGeAlD
Crizotinib—TYK2—nervous system—Parkinson's disease	0.000177	0.00139	CbGeAlD
Crizotinib—EPHB6—spinal cord—Parkinson's disease	0.000176	0.00138	CbGeAlD
Crizotinib—MAP3K2—central nervous system—Parkinson's disease	0.000175	0.00138	CbGeAlD
Crizotinib—EPHA4—cerebellum—Parkinson's disease	0.000175	0.00137	CbGeAlD
Crizotinib—YES1—midbrain—Parkinson's disease	0.000174	0.00137	CbGeAlD
Crizotinib—AURKA—brain—Parkinson's disease	0.000174	0.00137	CbGeAlD
Crizotinib—TESK1—brain—Parkinson's disease	0.000173	0.00136	CbGeAlD
Crizotinib—TAOK3—midbrain—Parkinson's disease	0.000172	0.00135	CbGeAlD
Crizotinib—PTK2—central nervous system—Parkinson's disease	0.000172	0.00135	CbGeAlD
Crizotinib—TBK1—central nervous system—Parkinson's disease	0.000172	0.00135	CbGeAlD
Crizotinib—RPS6KB1—nervous system—Parkinson's disease	0.000172	0.00135	CbGeAlD
Crizotinib—MAP3K2—cerebellum—Parkinson's disease	0.000171	0.00134	CbGeAlD
Crizotinib—TYK2—central nervous system—Parkinson's disease	0.000171	0.00134	CbGeAlD
Crizotinib—FGR—nervous system—Parkinson's disease	0.00017	0.00134	CbGeAlD
Crizotinib—YES1—spinal cord—Parkinson's disease	0.00017	0.00134	CbGeAlD
Crizotinib—JAK2—head—Parkinson's disease	0.00017	0.00133	CbGeAlD
Crizotinib—AXL—nervous system—Parkinson's disease	0.00017	0.00133	CbGeAlD
Crizotinib—TAOK3—spinal cord—Parkinson's disease	0.000168	0.00132	CbGeAlD
Crizotinib—MERTK—brain—Parkinson's disease	0.000168	0.00132	CbGeAlD
Crizotinib—EPHA2—head—Parkinson's disease	0.000168	0.00132	CbGeAlD
Crizotinib—TBK1—cerebellum—Parkinson's disease	0.000168	0.00132	CbGeAlD
Crizotinib—PTK2—cerebellum—Parkinson's disease	0.000168	0.00132	CbGeAlD
Crizotinib—TYK2—cerebellum—Parkinson's disease	0.000167	0.00131	CbGeAlD
Crizotinib—RPS6KB1—central nervous system—Parkinson's disease	0.000165	0.0013	CbGeAlD
Crizotinib—CSF1R—medulla oblongata—Parkinson's disease	0.000165	0.00129	CbGeAlD
Crizotinib—IRAK1—cerebellum—Parkinson's disease	0.000164	0.00129	CbGeAlD
Crizotinib—LIMK2—brain—Parkinson's disease	0.000164	0.00129	CbGeAlD
Crizotinib—FGR—central nervous system—Parkinson's disease	0.000164	0.00129	CbGeAlD
Crizotinib—TEK—head—Parkinson's disease	0.000164	0.00129	CbGeAlD
Crizotinib—MAP4K5—head—Parkinson's disease	0.000164	0.00129	CbGeAlD
Crizotinib—MAP3K3—head—Parkinson's disease	0.000164	0.00129	CbGeAlD
Crizotinib—SRC—spinal cord—Parkinson's disease	0.000164	0.00129	CbGeAlD
Crizotinib—NUAK2—brain—Parkinson's disease	0.000164	0.00128	CbGeAlD
Crizotinib—AXL—central nervous system—Parkinson's disease	0.000163	0.00128	CbGeAlD
Crizotinib—MAP3K12—brain—Parkinson's disease	0.000162	0.00128	CbGeAlD
Crizotinib—ACVR1—brain—Parkinson's disease	0.000162	0.00128	CbGeAlD
Crizotinib—RPS6KB1—cerebellum—Parkinson's disease	0.000161	0.00127	CbGeAlD
Crizotinib—JAK2—nervous system—Parkinson's disease	0.000161	0.00126	CbGeAlD
Crizotinib—AXL—cerebellum—Parkinson's disease	0.00016	0.00125	CbGeAlD
Crizotinib—STK35—brain—Parkinson's disease	0.000159	0.00125	CbGeAlD
Crizotinib—EPHA2—nervous system—Parkinson's disease	0.000159	0.00125	CbGeAlD
Crizotinib—EPHB6—head—Parkinson's disease	0.000157	0.00123	CbGeAlD
Crizotinib—TEK—nervous system—Parkinson's disease	0.000155	0.00122	CbGeAlD
Crizotinib—MAP4K5—nervous system—Parkinson's disease	0.000155	0.00122	CbGeAlD
Crizotinib—MAP3K3—nervous system—Parkinson's disease	0.000155	0.00122	CbGeAlD
Crizotinib—ABL2—brain—Parkinson's disease	0.000155	0.00122	CbGeAlD
Crizotinib—JAK2—central nervous system—Parkinson's disease	0.000155	0.00122	CbGeAlD
Crizotinib—SLK—cerebellum—Parkinson's disease	0.000154	0.00121	CbGeAlD
Crizotinib—EPHA2—central nervous system—Parkinson's disease	0.000153	0.0012	CbGeAlD
Crizotinib—BMP2K—brain—Parkinson's disease	0.000153	0.0012	CbGeAlD
Crizotinib—EPHB4—cerebellum—Parkinson's disease	0.000153	0.0012	CbGeAlD
Crizotinib—ABL1—cardiovascular system—Parkinson's disease	0.000153	0.0012	CbGeAlD
Crizotinib—JAK2—cerebellum—Parkinson's disease	0.000152	0.00119	CbGeAlD
Crizotinib—YES1—head—Parkinson's disease	0.000151	0.00119	CbGeAlD
Crizotinib—CSF1R—midbrain—Parkinson's disease	0.000151	0.00118	CbGeAlD
Crizotinib—STK10—head—Parkinson's disease	0.00015	0.00118	CbGeAlD
Crizotinib—MAP3K3—central nervous system—Parkinson's disease	0.00015	0.00117	CbGeAlD
Crizotinib—MAP4K5—central nervous system—Parkinson's disease	0.00015	0.00117	CbGeAlD
Crizotinib—TEK—central nervous system—Parkinson's disease	0.00015	0.00117	CbGeAlD
Crizotinib—TAOK3—head—Parkinson's disease	0.000149	0.00117	CbGeAlD
Crizotinib—EPHB6—nervous system—Parkinson's disease	0.000148	0.00117	CbGeAlD
Crizotinib—PTK2B—brain—Parkinson's disease	0.000148	0.00116	CbGeAlD
Crizotinib—CSF1R—spinal cord—Parkinson's disease	0.000147	0.00115	CbGeAlD
Crizotinib—RIPK2—brain—Parkinson's disease	0.000147	0.00115	CbGeAlD
Crizotinib—MAP3K3—cerebellum—Parkinson's disease	0.000146	0.00115	CbGeAlD
Crizotinib—MAP4K5—cerebellum—Parkinson's disease	0.000146	0.00115	CbGeAlD
Crizotinib—TEK—cerebellum—Parkinson's disease	0.000146	0.00115	CbGeAlD
Crizotinib—SRC—head—Parkinson's disease	0.000146	0.00114	CbGeAlD
Crizotinib—YES1—nervous system—Parkinson's disease	0.000143	0.00113	CbGeAlD
Crizotinib—EPHB6—central nervous system—Parkinson's disease	0.000143	0.00112	CbGeAlD
Crizotinib—STK10—nervous system—Parkinson's disease	0.000142	0.00112	CbGeAlD
Crizotinib—EPHA4—brain—Parkinson's disease	0.000142	0.00111	CbGeAlD
Crizotinib—TAOK3—nervous system—Parkinson's disease	0.000142	0.00111	CbGeAlD
Crizotinib—EPHB6—cerebellum—Parkinson's disease	0.00014	0.0011	CbGeAlD
Crizotinib—MAP3K2—brain—Parkinson's disease	0.000139	0.00109	CbGeAlD
Crizotinib—YES1—central nervous system—Parkinson's disease	0.000138	0.00108	CbGeAlD
Crizotinib—SRC—nervous system—Parkinson's disease	0.000138	0.00108	CbGeAlD
Crizotinib—STK10—central nervous system—Parkinson's disease	0.000137	0.00107	CbGeAlD
Crizotinib—TAOK3—central nervous system—Parkinson's disease	0.000136	0.00107	CbGeAlD
Crizotinib—PTK2—brain—Parkinson's disease	0.000136	0.00107	CbGeAlD
Crizotinib—TBK1—brain—Parkinson's disease	0.000136	0.00107	CbGeAlD
Crizotinib—TYK2—brain—Parkinson's disease	0.000135	0.00106	CbGeAlD
Crizotinib—YES1—cerebellum—Parkinson's disease	0.000135	0.00106	CbGeAlD
Crizotinib—STK10—cerebellum—Parkinson's disease	0.000134	0.00105	CbGeAlD
Crizotinib—IRAK1—brain—Parkinson's disease	0.000134	0.00105	CbGeAlD
Crizotinib—TAOK3—cerebellum—Parkinson's disease	0.000133	0.00105	CbGeAlD
Crizotinib—SRC—central nervous system—Parkinson's disease	0.000133	0.00104	CbGeAlD
Crizotinib—RPS6KB1—brain—Parkinson's disease	0.000131	0.00103	CbGeAlD
Crizotinib—CSF1R—head—Parkinson's disease	0.000131	0.00103	CbGeAlD
Crizotinib—ABL1—medulla oblongata—Parkinson's disease	0.00013	0.00102	CbGeAlD
Crizotinib—FGR—brain—Parkinson's disease	0.00013	0.00102	CbGeAlD
Crizotinib—SRC—cerebellum—Parkinson's disease	0.00013	0.00102	CbGeAlD
Crizotinib—AXL—brain—Parkinson's disease	0.00013	0.00102	CbGeAlD
Crizotinib—SLK—brain—Parkinson's disease	0.000125	0.000981	CbGeAlD
Crizotinib—EPHB4—brain—Parkinson's disease	0.000124	0.000974	CbGeAlD
Crizotinib—CSF1R—nervous system—Parkinson's disease	0.000124	0.000972	CbGeAlD
Crizotinib—JAK2—brain—Parkinson's disease	0.000123	0.000967	CbGeAlD
Crizotinib—EPHA2—brain—Parkinson's disease	0.000122	0.000955	CbGeAlD
Crizotinib—CSF1R—central nervous system—Parkinson's disease	0.000119	0.000936	CbGeAlD
Crizotinib—ABL1—midbrain—Parkinson's disease	0.000119	0.000935	CbGeAlD
Crizotinib—MAP4K5—brain—Parkinson's disease	0.000119	0.000932	CbGeAlD
Crizotinib—TEK—brain—Parkinson's disease	0.000119	0.000932	CbGeAlD
Crizotinib—MAP3K3—brain—Parkinson's disease	0.000119	0.000932	CbGeAlD
Crizotinib—CSF1R—cerebellum—Parkinson's disease	0.000117	0.000915	CbGeAlD
Crizotinib—ABL1—spinal cord—Parkinson's disease	0.000116	0.000912	CbGeAlD
Crizotinib—EPHB6—brain—Parkinson's disease	0.000113	0.000891	CbGeAlD
Crizotinib—YES1—brain—Parkinson's disease	0.00011	0.000861	CbGeAlD
Crizotinib—STK10—brain—Parkinson's disease	0.000109	0.000853	CbGeAlD
Crizotinib—TAOK3—brain—Parkinson's disease	0.000108	0.00085	CbGeAlD
Crizotinib—SRC—brain—Parkinson's disease	0.000105	0.000828	CbGeAlD
Crizotinib—ABL1—head—Parkinson's disease	0.000103	0.000811	CbGeAlD
Crizotinib—ABL1—nervous system—Parkinson's disease	9.79e-05	0.000769	CbGeAlD
Crizotinib—CSF1R—brain—Parkinson's disease	9.47e-05	0.000743	CbGeAlD
Crizotinib—ABL1—central nervous system—Parkinson's disease	9.43e-05	0.00074	CbGeAlD
Crizotinib—ABL1—cerebellum—Parkinson's disease	9.21e-05	0.000723	CbGeAlD
Crizotinib—ABL1—brain—Parkinson's disease	7.48e-05	0.000588	CbGeAlD
Crizotinib—ABCB1—embryo—Parkinson's disease	6.34e-05	0.000498	CbGeAlD
Crizotinib—ABCB1—forebrain—Parkinson's disease	5.61e-05	0.00044	CbGeAlD
Crizotinib—ABCB1—cardiovascular system—Parkinson's disease	4.74e-05	0.000372	CbGeAlD
Crizotinib—CYP3A4—nervous system—Parkinson's disease	4.3e-05	0.000338	CbGeAlD
Crizotinib—CYP3A4—central nervous system—Parkinson's disease	4.14e-05	0.000325	CbGeAlD
Crizotinib—ABCB1—medulla oblongata—Parkinson's disease	4.05e-05	0.000318	CbGeAlD
Crizotinib—ABCB1—midbrain—Parkinson's disease	3.7e-05	0.000291	CbGeAlD
Crizotinib—ABCB1—spinal cord—Parkinson's disease	3.61e-05	0.000284	CbGeAlD
Crizotinib—ABCB1—head—Parkinson's disease	3.21e-05	0.000252	CbGeAlD
Crizotinib—ABCB1—nervous system—Parkinson's disease	3.04e-05	0.000239	CbGeAlD
Crizotinib—ABCB1—central nervous system—Parkinson's disease	2.93e-05	0.00023	CbGeAlD
Crizotinib—ABCB1—cerebellum—Parkinson's disease	2.87e-05	0.000225	CbGeAlD
Crizotinib—ABCB1—brain—Parkinson's disease	2.33e-05	0.000183	CbGeAlD
Crizotinib—RIPK2—Signaling Pathways—INS—Parkinson's disease	3.11e-06	1.71e-05	CbGpPWpGaD
Crizotinib—JAK2—Axon guidance—IL6—Parkinson's disease	3.1e-06	1.7e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—TAC1—Parkinson's disease	3.08e-06	1.69e-05	CbGpPWpGaD
Crizotinib—ACVR1B—Signaling Pathways—IL6—Parkinson's disease	3.08e-06	1.69e-05	CbGpPWpGaD
Crizotinib—FER—Signaling Pathways—IL6—Parkinson's disease	3.08e-06	1.69e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—HTR2A—Parkinson's disease	3.08e-06	1.69e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—INS—Parkinson's disease	3.07e-06	1.68e-05	CbGpPWpGaD
Crizotinib—JAK2—Innate Immune System—MAPK8—Parkinson's disease	3.06e-06	1.68e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—ABL1—Parkinson's disease	3.05e-06	1.67e-05	CbGpPWpGaD
Crizotinib—LCK—Cytokine Signaling in Immune system—IL6—Parkinson's disease	3.05e-06	1.67e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—HTR2A—Parkinson's disease	3.04e-06	1.66e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—DDC—Parkinson's disease	3.03e-06	1.66e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—NGF—Parkinson's disease	3.02e-06	1.66e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—DRD2—Parkinson's disease	3.02e-06	1.66e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—DRD1—Parkinson's disease	3.02e-06	1.66e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—HTR7—Parkinson's disease	3.02e-06	1.66e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—MTHFR—Parkinson's disease	3.02e-06	1.66e-05	CbGpPWpGaD
Crizotinib—ABCB1—Transmembrane transport of small molecules—HMOX1—Parkinson's disease	3.01e-06	1.65e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling by NGF—IL6—Parkinson's disease	3e-06	1.64e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—NDUFB11—Parkinson's disease	2.99e-06	1.64e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—INSR—Parkinson's disease	2.95e-06	1.62e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—INS—Parkinson's disease	2.94e-06	1.61e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—NGF—Parkinson's disease	2.94e-06	1.61e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—DRD3—Parkinson's disease	2.93e-06	1.61e-05	CbGpPWpGaD
Crizotinib—LYN—Developmental Biology—TNF—Parkinson's disease	2.93e-06	1.6e-05	CbGpPWpGaD
Crizotinib—AXL—Signaling Pathways—IL6—Parkinson's disease	2.92e-06	1.6e-05	CbGpPWpGaD
Crizotinib—TYK2—Developmental Biology—IL6—Parkinson's disease	2.92e-06	1.6e-05	CbGpPWpGaD
Crizotinib—ABL1—Developmental Biology—TNF—Parkinson's disease	2.91e-06	1.6e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—HTR2A—Parkinson's disease	2.88e-06	1.58e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—HGF—Parkinson's disease	2.87e-06	1.57e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—APOE—Parkinson's disease	2.86e-06	1.57e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—GSTA4—Parkinson's disease	2.86e-06	1.57e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GCH1—Parkinson's disease	2.85e-06	1.56e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—INS—Parkinson's disease	2.85e-06	1.56e-05	CbGpPWpGaD
Crizotinib—PTK2—Innate Immune System—IL6—Parkinson's disease	2.84e-06	1.56e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—APOE—Parkinson's disease	2.82e-06	1.55e-05	CbGpPWpGaD
Crizotinib—PTK2—Immune System—IL1B—Parkinson's disease	2.82e-06	1.55e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—APOE—Parkinson's disease	2.81e-06	1.54e-05	CbGpPWpGaD
Crizotinib—YES1—Innate Immune System—IL6—Parkinson's disease	2.8e-06	1.53e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—HTR2A—Parkinson's disease	2.79e-06	1.53e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—FGB—Parkinson's disease	2.79e-06	1.53e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—IL1B—Parkinson's disease	2.78e-06	1.53e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—HTR1A—Parkinson's disease	2.77e-06	1.52e-05	CbGpPWpGaD
Crizotinib—JAK2—Developmental Biology—TNF—Parkinson's disease	2.74e-06	1.5e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—ADRBK1—Parkinson's disease	2.73e-06	1.5e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TAC1—Parkinson's disease	2.73e-06	1.5e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—IGF2—Parkinson's disease	2.71e-06	1.48e-05	CbGpPWpGaD
Crizotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—Parkinson's disease	2.69e-06	1.47e-05	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—MAPK8—Parkinson's disease	2.68e-06	1.47e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—DRD1—Parkinson's disease	2.68e-06	1.47e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—APOE—Parkinson's disease	2.68e-06	1.47e-05	CbGpPWpGaD
Crizotinib—BMPR1B—Signaling Pathways—IL6—Parkinson's disease	2.67e-06	1.46e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling by NGF—IL6—Parkinson's disease	2.65e-06	1.45e-05	CbGpPWpGaD
Crizotinib—IRAK1—Innate Immune System—IL6—Parkinson's disease	2.65e-06	1.45e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—HTR7—Parkinson's disease	2.65e-06	1.45e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—DRD2—Parkinson's disease	2.65e-06	1.45e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—MTHFR—Parkinson's disease	2.65e-06	1.45e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—IL1B—Parkinson's disease	2.64e-06	1.45e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—IGF1R—Parkinson's disease	2.62e-06	1.44e-05	CbGpPWpGaD
Crizotinib—TBK1—Immune System—IL6—Parkinson's disease	2.61e-06	1.43e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—CASP3—Parkinson's disease	2.6e-06	1.43e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—APOE—Parkinson's disease	2.6e-06	1.42e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—DRD3—Parkinson's disease	2.59e-06	1.42e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—EDN1—Parkinson's disease	2.59e-06	1.42e-05	CbGpPWpGaD
Crizotinib—PTK2—Immune System—MAPK8—Parkinson's disease	2.59e-06	1.42e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling by GPCR—IL6—Parkinson's disease	2.59e-06	1.42e-05	CbGpPWpGaD
Crizotinib—TYK2—Innate Immune System—IL6—Parkinson's disease	2.58e-06	1.41e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PLA2G6—Parkinson's disease	2.57e-06	1.41e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—IL1B—Parkinson's disease	2.56e-06	1.4e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—MAPK8—Parkinson's disease	2.55e-06	1.4e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—MAOB—Parkinson's disease	2.55e-06	1.4e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—FBP1—Parkinson's disease	2.54e-06	1.39e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—DBH—Parkinson's disease	2.54e-06	1.39e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GBA—Parkinson's disease	2.54e-06	1.39e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—IGF2—Parkinson's disease	2.53e-06	1.39e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—CYP2D6—Parkinson's disease	2.51e-06	1.38e-05	CbGpPWpGaD
Crizotinib—MAP3K3—Immune System—IL6—Parkinson's disease	2.5e-06	1.37e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—CTGF—Parkinson's disease	2.46e-06	1.35e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—APOE—Parkinson's disease	2.46e-06	1.35e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—IGF1R—Parkinson's disease	2.45e-06	1.34e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—INS—Parkinson's disease	2.44e-06	1.34e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—ADRBK1—Parkinson's disease	2.42e-06	1.33e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—EDN1—Parkinson's disease	2.42e-06	1.33e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—MAPK8—Parkinson's disease	2.42e-06	1.33e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—INS—Parkinson's disease	2.41e-06	1.32e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—INS—Parkinson's disease	2.4e-06	1.32e-05	CbGpPWpGaD
Crizotinib—SRC—Axon guidance—IL6—Parkinson's disease	2.4e-06	1.32e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—MAPK8—Parkinson's disease	2.39e-06	1.31e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—NGF—Parkinson's disease	2.38e-06	1.3e-05	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—MAPK8—Parkinson's disease	2.37e-06	1.3e-05	CbGpPWpGaD
Crizotinib—JAK3—Immune System—IL6—Parkinson's disease	2.36e-06	1.29e-05	CbGpPWpGaD
Crizotinib—LYN—Developmental Biology—IL6—Parkinson's disease	2.36e-06	1.29e-05	CbGpPWpGaD
Crizotinib—ABL1—Developmental Biology—IL6—Parkinson's disease	2.35e-06	1.29e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—MAPK8—Parkinson's disease	2.35e-06	1.29e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—DRD2—Parkinson's disease	2.34e-06	1.29e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—HTR7—Parkinson's disease	2.34e-06	1.29e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—MTHFR—Parkinson's disease	2.34e-06	1.28e-05	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—IL6—Parkinson's disease	2.34e-06	1.28e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—CASP3—Parkinson's disease	2.32e-06	1.27e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—CYP2E1—Parkinson's disease	2.3e-06	1.26e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—INS—Parkinson's disease	2.29e-06	1.25e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—CASP3—Parkinson's disease	2.29e-06	1.25e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—NQO1—Parkinson's disease	2.27e-06	1.24e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—HTR2A—Parkinson's disease	2.26e-06	1.24e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—TH—Parkinson's disease	2.24e-06	1.23e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—NGF—Parkinson's disease	2.22e-06	1.22e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—INS—Parkinson's disease	2.22e-06	1.22e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—IGF2—Parkinson's disease	2.22e-06	1.22e-05	CbGpPWpGaD
Crizotinib—JAK2—Developmental Biology—IL6—Parkinson's disease	2.21e-06	1.21e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—CASP3—Parkinson's disease	2.19e-06	1.2e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—APOE—Parkinson's disease	2.18e-06	1.2e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—CYCS—Parkinson's disease	2.15e-06	1.18e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—IGF1R—Parkinson's disease	2.15e-06	1.18e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—MAPK8—Parkinson's disease	2.13e-06	1.17e-05	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—TNF—Parkinson's disease	2.12e-06	1.16e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—CASP3—Parkinson's disease	2.12e-06	1.16e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—EDN1—Parkinson's disease	2.12e-06	1.16e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—HTR2A—Parkinson's disease	2.12e-06	1.16e-05	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—IL6—Parkinson's disease	2.11e-06	1.16e-05	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—IL6—Parkinson's disease	2.11e-06	1.15e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—APOE—Parkinson's disease	2.1e-06	1.15e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—INS—Parkinson's disease	2.1e-06	1.15e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—MAPK8—Parkinson's disease	2.1e-06	1.15e-05	CbGpPWpGaD
Crizotinib—LYN—Innate Immune System—IL6—Parkinson's disease	2.09e-06	1.14e-05	CbGpPWpGaD
Crizotinib—ABL1—Innate Immune System—IL6—Parkinson's disease	2.08e-06	1.14e-05	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—IL6—Parkinson's disease	2.07e-06	1.14e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—IL1B—Parkinson's disease	2.07e-06	1.14e-05	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—IL6—Parkinson's disease	2.07e-06	1.13e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—IL1B—Parkinson's disease	2.06e-06	1.13e-05	CbGpPWpGaD
Crizotinib—CDK7—Disease—IL6—Parkinson's disease	2.04e-06	1.12e-05	CbGpPWpGaD
Crizotinib—BLK—Immune System—IL6—Parkinson's disease	2.03e-06	1.11e-05	CbGpPWpGaD
Crizotinib—FGR—Immune System—IL6—Parkinson's disease	2.02e-06	1.11e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—MAPK8—Parkinson's disease	2.01e-06	1.1e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—APOE—Parkinson's disease	1.97e-06	1.08e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IGF2—Parkinson's disease	1.96e-06	1.08e-05	CbGpPWpGaD
Crizotinib—JAK2—Innate Immune System—IL6—Parkinson's disease	1.95e-06	1.07e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—MAPK8—Parkinson's disease	1.95e-06	1.07e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—NGF—Parkinson's disease	1.95e-06	1.07e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—IL1B—Parkinson's disease	1.94e-06	1.06e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—COMT—Parkinson's disease	1.9e-06	1.04e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—MAPK8—Parkinson's disease	1.9e-06	1.04e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IGF1R—Parkinson's disease	1.9e-06	1.04e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—CYP2D6—Parkinson's disease	1.89e-06	1.04e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—MAPK8—Parkinson's disease	1.89e-06	1.04e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—GSTP1—Parkinson's disease	1.89e-06	1.04e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—MAOA—Parkinson's disease	1.89e-06	1.04e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—EDN1—Parkinson's disease	1.88e-06	1.03e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—HMOX1—Parkinson's disease	1.87e-06	1.02e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—DDC—Parkinson's disease	1.87e-06	1.02e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—INS—Parkinson's disease	1.86e-06	1.02e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—CTGF—Parkinson's disease	1.86e-06	1.02e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—HTR2A—Parkinson's disease	1.86e-06	1.02e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—CASP3—Parkinson's disease	1.82e-06	9.98e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—INS—Parkinson's disease	1.8e-06	9.85e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—CASP3—Parkinson's disease	1.79e-06	9.84e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—ABCB1—Parkinson's disease	1.79e-06	9.83e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—MAPK8—Parkinson's disease	1.78e-06	9.76e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GSTA4—Parkinson's disease	1.76e-06	9.66e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—GSTM1—Parkinson's disease	1.74e-06	9.54e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—CYP2E1—Parkinson's disease	1.73e-06	9.5e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—NGF—Parkinson's disease	1.73e-06	9.46e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—APOE—Parkinson's disease	1.72e-06	9.45e-06	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—IL6—Parkinson's disease	1.71e-06	9.4e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—NQO1—Parkinson's disease	1.71e-06	9.39e-06	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—IL6—Parkinson's disease	1.71e-06	9.37e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—CASP3—Parkinson's disease	1.7e-06	9.33e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—IL1B—Parkinson's disease	1.7e-06	9.32e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—TH—Parkinson's disease	1.69e-06	9.26e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—INS—Parkinson's disease	1.68e-06	9.22e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—MAPK8—Parkinson's disease	1.67e-06	9.17e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—GPX1—Parkinson's disease	1.67e-06	9.14e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—CASP3—Parkinson's disease	1.65e-06	9.06e-06	CbGpPWpGaD
Crizotinib—PTK2—Immune System—IL6—Parkinson's disease	1.65e-06	9.06e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—MAPK8—Parkinson's disease	1.65e-06	9.04e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—HTR2A—Parkinson's disease	1.64e-06	9e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—IL6—Parkinson's disease	1.64e-06	9e-06	CbGpPWpGaD
Crizotinib—YES1—Immune System—IL6—Parkinson's disease	1.63e-06	8.93e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—CYCS—Parkinson's disease	1.62e-06	8.89e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PLA2G6—Parkinson's disease	1.59e-06	8.7e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—MAOB—Parkinson's disease	1.57e-06	8.61e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—MAPK8—Parkinson's disease	1.56e-06	8.58e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—MAPK8—Parkinson's disease	1.56e-06	8.55e-06	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—IL6—Parkinson's disease	1.55e-06	8.47e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—MTHFR—Parkinson's disease	1.54e-06	8.43e-06	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—IL6—Parkinson's disease	1.53e-06	8.37e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—APOE—Parkinson's disease	1.53e-06	8.37e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—MAPK8—Parkinson's disease	1.52e-06	8.33e-06	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—IL6—Parkinson's disease	1.51e-06	8.3e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—IL1B—Parkinson's disease	1.51e-06	8.25e-06	CbGpPWpGaD
Crizotinib—TYK2—Immune System—IL6—Parkinson's disease	1.5e-06	8.22e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—INS—Parkinson's disease	1.47e-06	8.08e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—COMT—Parkinson's disease	1.44e-06	7.87e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—APOE—Parkinson's disease	1.43e-06	7.85e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—GSTP1—Parkinson's disease	1.43e-06	7.83e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—MAOA—Parkinson's disease	1.43e-06	7.81e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—HMOX1—Parkinson's disease	1.41e-06	7.73e-06	CbGpPWpGaD
Crizotinib—TYK2—Disease—IL6—Parkinson's disease	1.38e-06	7.59e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—MAPK8—Parkinson's disease	1.38e-06	7.57e-06	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—IL6—Parkinson's disease	1.36e-06	7.46e-06	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—IL6—Parkinson's disease	1.34e-06	7.35e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CASP3—Parkinson's disease	1.34e-06	7.34e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—GSTM1—Parkinson's disease	1.31e-06	7.2e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—INS—Parkinson's disease	1.3e-06	7.15e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—IL6—Parkinson's disease	1.28e-06	7.04e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—GPX1—Parkinson's disease	1.26e-06	6.89e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CASP3—Parkinson's disease	1.25e-06	6.87e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—IL6—Parkinson's disease	1.24e-06	6.83e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—IL6—Parkinson's disease	1.24e-06	6.82e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—MAPK8—Parkinson's disease	1.23e-06	6.74e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—INS—Parkinson's disease	1.22e-06	6.7e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—IL6—Parkinson's disease	1.21e-06	6.66e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—IL6—Parkinson's disease	1.21e-06	6.63e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CYP2D6—Parkinson's disease	1.17e-06	6.4e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—MTHFR—Parkinson's disease	1.16e-06	6.36e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—MAPK8—Parkinson's disease	1.15e-06	6.31e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CTGF—Parkinson's disease	1.15e-06	6.28e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—IL6—Parkinson's disease	1.14e-06	6.23e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CASP3—Parkinson's disease	1.1e-06	6.01e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—APOE—Parkinson's disease	1.08e-06	5.92e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—IL6—Parkinson's disease	1.07e-06	5.86e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CYP2E1—Parkinson's disease	1.07e-06	5.85e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—NQO1—Parkinson's disease	1.06e-06	5.79e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—IL6—Parkinson's disease	1.05e-06	5.77e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—IL6—Parkinson's disease	1.05e-06	5.75e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—TH—Parkinson's disease	1.04e-06	5.7e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MAPK8—Parkinson's disease	1.01e-06	5.53e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—IL6—Parkinson's disease	9.99e-07	5.48e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CYCS—Parkinson's disease	9.99e-07	5.48e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—IL6—Parkinson's disease	9.96e-07	5.46e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CASP3—Parkinson's disease	9.71e-07	5.32e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—IL6—Parkinson's disease	9.7e-07	5.32e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—INS—Parkinson's disease	9.23e-07	5.06e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—IL6—Parkinson's disease	9.19e-07	5.04e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MAPK8—Parkinson's disease	8.92e-07	4.89e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—COMT—Parkinson's disease	8.84e-07	4.85e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—IL6—Parkinson's disease	8.81e-07	4.83e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GSTP1—Parkinson's disease	8.8e-07	4.83e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—MAOA—Parkinson's disease	8.78e-07	4.81e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—HMOX1—Parkinson's disease	8.68e-07	4.76e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ABCB1—Parkinson's disease	8.33e-07	4.57e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—IL6—Parkinson's disease	8.14e-07	4.46e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GSTM1—Parkinson's disease	8.09e-07	4.43e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—IL6—Parkinson's disease	7.85e-07	4.31e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GPX1—Parkinson's disease	7.75e-07	4.25e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—IL6—Parkinson's disease	7.35e-07	4.03e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—MTHFR—Parkinson's disease	7.15e-07	3.92e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—APOE—Parkinson's disease	6.66e-07	3.65e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—IL6—Parkinson's disease	6.44e-07	3.53e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IL6—Parkinson's disease	5.7e-07	3.12e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—INS—Parkinson's disease	5.69e-07	3.12e-06	CbGpPWpGaD
